×
×

News Artikel

HERMES PHARMA has continued to see steady growth over the last 20 years. (click to enlarge image)

Dr Thomas Hein, Senior Vice President Commercial & Regulatory Affairs, HERMES PHARMA

Dr Andreas Schrepfer, Managing Director, HERMES PHARMA

HERMES PHARMA announces spin-out from HERMES Arzneimittel

The forward-looking change marks a new phase for HERMES PHARMA bringing greater independence while retaining long-term stability for its third party customers.

Pullach, Germany, 01 July 2021 – HERMES PHARMA, previously a division of HERMES Arzneimittel GmbH, today announces that it has formed a separate legal entity named HERMES PHARMA GmbH. The forward-looking change will see both HERMES PHARMA GmbH and HERMES Arzneimittel GmbH operating independently but remaining part of the Johannes Burges Family Foundation. The move marks a new phase for HERMES PHARMA bringing greater independence while retaining long-term stability for the company’s third-party business.

 

HERMES PHARMA is a CDMO specializing in the development and manufacture of user-friendly oral dosage forms for healthcare companies around the world. Services cover the entire pharmaceutical value chain – from new product development through to manufacturing and regulatory support. As a division, HERMES PHARMA has continued to see steady growth over the last 20 years. Annual turnover has increased sevenfold, achieving more than €140 million in 2020, and the division has quadrupled the size of its team.

 

The consistent growth and maturity of the organization has made it necessary to adjust its structure to better meet future needs. Dr Thomas Hein, Senior Vice President Commercial & Regulatory Affairs, commented, “Becoming an independent company will provide HERMES PHARMA with increased flexibility, making us more agile in our management decisions. We will be able to focus our investments to best meet the needs of our customers, whether that’s through new technology, enhanced sustainability, or optimized supply agreements. We highly value our long-term customer relations, which we regard as a strategic asset, and look forward to a long future of open and trust-based partnerships.”

 

HERMES PHARMA GmbH will move forward with the existing management team in place. Dr Andreas Schrepfer, Managing Director, said, “HERMES Arzneimittel has a long history of pharmaceutical excellence – more than 100 years, in fact. This reorganization is part of a long-term strategy that will build on our heritage and position us to foster future growth. Remaining in the Johannes Burges Family Foundation will help ensure our financial stability.”

 

For more information about HERMES PHARMA, please visit www.hermes-pharma.com

 

About HERMES PHARMA
HERMES PHARMA is the leading expert in developing and manufacturing user-friendly oral dosage forms, including effervescent and chewable tablets, instant drinks, lozenges, orally disintegrating granules and the newly developed HERMES NutriCaps. As a contract development and manufacturing organization (CDMO), we offer customized services along the entire pharmaceutical value chain, from new product development and formulation to manufacturing and regulatory support. For more than 40 years, leading healthcare companies around the globe have worked with HERMES PHARMA to expand their pharmaceutical and nutraceutical product lines as well as to grow their brands.

 

Our sister company HERMES Arzneimittel has a rich portfolio of successful OTC brands and a history of more than a hundred years in pharmaceutical excellence. This heritage makes HERMES PHARMA a reliable and experienced partner who truly understands the challenges of its customers. Further information is available at www.hermes-pharma.com

 

 

For media enquiries:
Helen Stewart-Miller
PR Specialist BioStrata
hstewartmiller@biostratamarketing.com
+44 (0)1223 627120

For more information:
Eva Tietz Senior Manager Marketing & PR
HERMES PHARMA GmbH
eva.tietz@hermes-pharma.com

 

 

Back